ArticleJournal of clinical microbiology2025
Comparison of the BluePoint MoldID oligonucleotide array and Bruker Biotyper MALDI-TOF MS for the identification of filamentous fungi.
Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BluePoint MoldID can identify 43 fungal species through nucleic acid array hybridization and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) can identify 247 filamentous fungi through mass spectrometry. First, 43 standard isolates from the Bioresource Collection and Research Center, Taiwan, and the College of American Pathologists and 41 clinical IMPORTANCE: The BluePoint MoldID kit is an oligonucleotide array used for the identification of filamentous fungi, and it has not yet been mentioned in recent studies. We used a BluePoint MoldID kit to identify standard and clinical filamentous fungal isolates and compared its performance with that of Bruker MALDI-TOF MS. The former accurately identified 80.2% of the isolates (142/177), and the latter identified 92.6% of the isolates (164/177). The performance of the BluePoint MoldID kit was slightly inferior to that of Bruker MALDI-TOF MS because of the smaller database. However, the BluePoint MoldID kit can cover most clinically common opportunistic fungal infections; thus, it offers an alternative method for laboratories that lack MALDI-TOF MS equipment, as the device is less expensive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.